These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84. A preliminary evaluation of magnesium pemoline in chronic schizophrenic patients. Bishop MP; Gallant DM; Thompson RD Am J Psychiatry; 1968 Jan; 124(7):982-6. PubMed ID: 4383523 [No Abstract] [Full Text] [Related]
85. Inappropriate pemoline therapy leading to acute liver failure and liver transplantation. Abbiati C; Vecchi M; Rossi G; Donata MF; de Franchis R Dig Liver Dis; 2002 Jun; 34(6):447-51. PubMed ID: 12132793 [TBL] [Abstract][Full Text] [Related]
86. Measurement of whole blood serotonin as a guide in prescribing psychostimulant medication for children with attentional deficits. Saul RC; Ashby CD Clin Neuropharmacol; 1986; 9(2):189-95. PubMed ID: 3708603 [TBL] [Abstract][Full Text] [Related]
89. Pemoline induced acute choreoathetosis: case report and review of the literature. Stork CM; Cantor R J Toxicol Clin Toxicol; 1997; 35(1):105-8. PubMed ID: 9022662 [TBL] [Abstract][Full Text] [Related]
90. Methamphetamine and fluoxetine treatment of a child with attention-deficit hyperactivity disorder and obsessive-compulsive disorder. Bussing R; Levin GM J Child Adolesc Psychopharmacol; 1993; 3(1):53-8. PubMed ID: 19630596 [TBL] [Abstract][Full Text] [Related]
91. Unexpected consequence of treatment for attention deficit disorder. Merrill RD; Garfinkel B Am J Psychiatry; 1987 Feb; 144(2):250. PubMed ID: 3492932 [No Abstract] [Full Text] [Related]
92. Analysis of pemoline in serum by high performance liquid chromatography: clinical application to optimize treatment of hyperactive children. Tomkins CP; Soldin SJ; MacLeod SM; Rochefort JG; Swanson JM Ther Drug Monit; 1980; 2(3):255-60. PubMed ID: 7222180 [TBL] [Abstract][Full Text] [Related]
93. THE TRIAL OF A NEW STIMULANT, PEMOLINE, IN THE TREATMENT OF FATIGUE IN STUDENTS. LUCAS CJ; KNOWLES JB J Am Coll Health Assoc; 1963 Dec; 12():187-94. PubMed ID: 14134049 [No Abstract] [Full Text] [Related]
94. The Pemoline Model of Self-Injurious Behavior: An Update. Devine DP Methods Mol Biol; 2019; 2011():95-103. PubMed ID: 31273695 [TBL] [Abstract][Full Text] [Related]
95. Selfaggressiveness: a new type of behavioral change induced by pemoline. Genovese E; Napoli PA; Bolego-Zonta N Life Sci; 1969 May; 8(9):513-5. PubMed ID: 4389346 [No Abstract] [Full Text] [Related]
96. Pemoline-induced choreoathetosis and rhabdomyolysis. Briscoe JG; Curry SC; Gerkin RD; Ruiz RR Med Toxicol Adverse Drug Exp; 1988; 3(1):72-6. PubMed ID: 3367787 [TBL] [Abstract][Full Text] [Related]
97. Pemoline. An alternative psychostimulant for the management of depressive disorders in cancer patients. Breitbart W; Mermelstein H Psychosomatics; 1992; 33(3):352-6. PubMed ID: 1410212 [No Abstract] [Full Text] [Related]